How many drugs treat Neuromyelitis optica?

Drug Landscape tracks 7 marketed treatments for Neuromyelitis optica (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/neuromyelitis-optica.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Neuromyelitis optica — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neuromyelitis optica (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Neuromyelitis optica, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Uplizna	INEBILIZUMAB	Viela Bio	CD19-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD19	2020-01-01
H5G1.1	ECULIZUMAB	AstraZeneca	Complement Inhibitor [EPC]	C5	2007-01-01
Mabthera	rituxan	Roche	CD20-directed Cytolytic Antibody	B-lymphocyte antigen CD20	1997-01-01
Mabthera	Rituximab-Pvvr	Roche	Monoclonal antibody	CD20 antigen on pre-B and mature B-lymphocytes	1997-01-01
Mabthera	rituximab	Roche	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	1997-01-01
UPLIZNA	INEBILIZUMAB-CDON	VIELA BIO	CD19-directed Cytolytic Antibody [EPC]	Low affinity immunoglobulin gamma Fc region receptor III-A, B-lymphocyte antigen CD19
Soliris	Soliris	Apellis Pharmaceuticals, Inc.		Complement C5

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Roche · 3 drugs in Neuromyelitis optica
Apellis Pharmaceuticals, Inc. · 1 drug in Neuromyelitis optica
AstraZeneca · 1 drug in Neuromyelitis optica
VIELA BIO · 1 drug in Neuromyelitis optica
Viela Bio · 1 drug in Neuromyelitis optica

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Neuromyelitis optica:

Cite this brief

Drug Landscape (2026). Neuromyelitis optica — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/neuromyelitis-optica. Accessed 2026-06-10.

Neuromyelitis optica full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing